Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer

He,Jinsong; Chen,Weicai; Wu,Huisheng; Wang,Min; Wang,Yuan; She,Xiaojia; Song,Shufen; Guan,Hong; Wang,Xianming

doi:10.3892/ol.2012.911

Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer

Authors:
- Jinsong He
- Weicai Chen
- Huisheng Wu
- Min Wang
- Yuan Wang
- Xiaojia She
- Shufen Song
- Hong Guan
- Xianming Wang
View Affiliations

Affiliations: Center of Breast Diseases, Second Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China, Center of Breast Diseases, Second Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China, Department of Pathology, Second Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, P.R. China
Published online on: September 12, 2012 https://doi.org/10.3892/ol.2012.911
Pages: 1209-1212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the correlation between breast cancer-specific gene 1 (BCSG1) and the effect of neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Real-time RT-PCR and immunohistochemistry were used to determine the expression of BCSG1 mRNA and protein levels of 32 TNBC patients before and after NAC. Tumor size was reduced significantly after NAC in all 32 TNBC patients. The expression of BCSG1 was also decreased after NAC at both mRNA and protein levels. There was a negative correlation between BCSG1 levels after NAC and the effect of NAC. BCSG1 may be a potential target for NAC in the treatment of TNBC.

View Figures

View References

1.	G CuriglianoA GoldhirschThe triple-negative subtype: new ideas for the poorest prognosis breast cancerJ Natl Cancer Inst Monogr2011108110201110.1093/jncimonographs/lgr03822043054
2.	H JiYE LiuT JiaIdentification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencingCancer Res5775976419979044857
3.	K WuZ WengQ TaoStage-specific expression of breast cancer-specific gene gamma-synucleinCancer Epidemiol Biomarkers Prev12920925200314504205
4.	T JiaYE LiuJ LiuYE ShiStimulation of breast cancer invasion and metastasis by synuclein gammaCancer Res5974274719999973226
5.	J GuoC ShouL MengNeuronal protein synuclein gamma predicts poor clinical outcome in breast cancerInt J Cancer12112961305200710.1002/ijc.2276317534899
6.	K WuZ QuanZ WengExpression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosisBreast Cancer Res Treat101259267200710.1007/s10549-006-9296-716821081
7.	A BoschP ErolesR ZaragozaJR ViñaA LluchTriple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of researchCancer Treat Rev36206215201010.1016/j.ctrv.2009.12.00220060649
8.	SK MohsinM ZhangGM ClarkD Craig AllredMaspin expression in invasive breast cancer: association with other prognostic factorsJ Pathol199432435200310.1002/path.131912635133
9.	Z NahlehNeoadjuvant chemotherapy for ‘triple negative’ breast cancer: a review of current practice and future outlookMed Oncol275315392010
10.	S CleatorW HellerRC CoombesTriple-negative breast cancer: therapeutic optionsLancet Oncol8235244200710.1016/S1470-2045(07)70074-817329194
11.	H FarmerN McCabeCJ LordTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature434917921200510.1038/nature0344515829967
12.	K RatnamJA LowCurrent development of clinical inhibitors of poly(ADP-ribose) polymerase in oncologyClin Cancer Res1313831388200710.1158/1078-0432.CCR-06-226017332279